<DOC>
	<DOCNO>NCT01388309</DOCNO>
	<brief_summary>This observational study evaluate clinical practice change Disease Activity Score ( DAS28 ) patient rheumatoid arthritis inadequate response DMARDs initiate treatment RoActemra/Actemra ( tocilizumab ) . Data collect eligible patient ( 8 mg/kg 4 mg/kg intravenously every 4 week , without methotrexate ) 12 month .</brief_summary>
	<brief_title>An Observational Study RoActemra/Actemra ( Tocilizumab ) Patients With Rheumatoid Arthritis Who Have Inadequate Response DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe active rheumatoid arthritis Inadequate response intolerance previous therapy one traditional DMARDs Pregnant lactate woman Active infection Positive hepatitis B , hepatitis C HIV infection Concomitant antiTNF drug Contraindications treatment RoActemra/Actemra</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>